AbbVie Inc (ABBV) Q2 2026 Earnings Preview: What to Watch
AbbVie reports Q2 2026 earnings on July 31. Analysts watch Skyrizi and Rinvoq growth to offset Humira declines amid a $291 million IPR&D charge.
The setup
AbbVie enters the July 31 earnings print under pressure to prove that its immunology portfolio can sustain momentum. The market is currently pricing in a cautious outlook, with Zacks Equity Research assigning a Rank #3 (Hold) to the stock.
Management has previously expressed confidence in exceeding peak consensus estimates for its key immunology brands. However, the recent guidance revision has introduced volatility into the valuation model, forcing investors to re-evaluate the company's long-term growth trajectory.
- Goldman Sachs maintains a Neutral rating with a $244 price target, citing valuation concerns.
- Cantor Fitzgerald holds an Overweight rating with a $265 target, citing confidence in the long-term pipeline.
- Zacks Equity Research reports an Earnings ESP of -1.01%, signaling a potential downside risk to consensus estimates.
Consensus numbers
The consensus estimate for Q2 2026 EPS sits at approximately $3.60 to $3.66. Revenue is expected to reach $16.78 billion, reflecting the ongoing transition away from Humira-dependent revenue streams.
Historical performance shows a pattern of beating estimates, though the recent IPR&D charge complicates the current quarter's comparison.
- Q2 2026 EPS Estimate: $3.60–$3.66.
- Q2 2026 Revenue Estimate: $16.78 billion.
- Q4 2025 Actual EPS: $1.86 vs $1.77 estimated.
- Q1 2026 Actual EPS: $2.71 vs $2.65 estimated.
- Q2 2026 Actual EPS: $2.65 vs $2.59 estimated.
- Beat probability: 45%; Miss probability: 35%; Inline probability: 20%.
What we'll watch on the call
The primary focus remains on the volume growth of Skyrizi and Rinvoq. Investors need to see these assets effectively absorbing the pricing pressure currently affecting the broader immunology segment.
Management's commentary on the $291 million IPR&D charge will be scrutinized for clues regarding future M&A activity. Additionally, any updates on the FDA's request for manufacturing data on trenibotulinumtoxinE will be a key catalyst for the aesthetics portfolio.
- Can Skyrizi and Rinvoq volume growth continue to offset Humira's erosion without further pricing headwinds?
- How should investors interpret the $291 million IPR&D charge in the context of future M&A strategy?
- Are there any updates regarding the FDA's request for additional manufacturing information for trenibotulinumtoxinE?
- What is the latest outlook on the recovery of the Aesthetics portfolio?
- How are currency fluctuations impacting the bottom line compared to previous quarters?
Fintwit's AI verdict
The current market sentiment reflects a tug-of-war between the company's strong growth drivers and the macro-level regulatory risks. While the recent guidance adjustment has dampened near-term expectations, the underlying fundamentals of the immunology segment remain a point of interest for institutional buyers.
The upcoming earnings call will likely serve as a binary event for the stock's performance through the remainder of the year. Investors are looking for clarity on whether the recent dip represents a buying opportunity or a structural shift in the company's margin profile.